Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.

Cytogenetic analysis was performed in 47 newly diagnosed patients with agnogenic myeloid metaplasia (AMM); 32 had a normal karyotype (68%, group I), whereas 15 had clonal abnormalities (32%, group II). The most frequent abnormal findings were a 20q- deletion in six cases (either alone or within complex anomalies), interstitial 13q- deletion in three cases (and monosomy 13 in one case), and acquired trisomy 21 or 21p+ in three cases. Four cases exhibited complex aberrations involving several chromosomes, sometimes with a mosaicism. In two patients with an initial abnormal karyotype, further cytogenetic analysis during the disease course showed the appearance of additional clonal anomalies, and particularly of a probable Philadelphia (Ph1) variant in one case. Treatment was essentially supportive. Survival was significantly shorter in group II (median, 30 months) compared with group I (median, not reached at 6 years; P = .015). In univariate analysis, other parameters significantly associated with a poor prognosis (P less than .05) were higher age, anemia, and increased percentage of circulating blasts. However, in a multivariate analysis, only cytogenetic abnormalities and age retained their independent prognostic value.

[1]  C. Dray,et al.  Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia. , 1987, Cancer genetics and cytogenetics.

[2]  J. Rowley,et al.  Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes , 1986 .

[3]  J. Rowley,et al.  Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. , 1986, Blood.

[4]  M. Oken,et al.  Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. , 1986, Blood.

[5]  J. Rowley,et al.  c-src is consistently conserved in the chromosomal deletion (20q) observed in myeloid disorders. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Rowley,et al.  The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis , 1985, Cancer.

[7]  A. Chapelle,et al.  Abnormalities of chromosome 13 in myelofibrosis. , 2009, Scandinavian journal of haematology.

[8]  S. Mirto,et al.  Cytogenetic studies in five patients with myelofibrosis and myeloid metaplasia. , 1984, Cancer genetics and cytogenetics.

[9]  F. Koppitch,et al.  Karyotypic polymorphism in acute myelofibrosis. , 1982, Blood.

[10]  P. Nowell,et al.  Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival , 1982, Cancer.

[11]  N. Kamada,et al.  Primary myelofibrosis with myeloid metaplasia and cytogenetically abnormal clones in 2 children with Down's syndrome. , 2009, Scandinavian journal of haematology.

[12]  W. R. Breg,et al.  Loss of Rh antigen associated with acquired Rh antibodies and a chromosome translocation in a patient with myeloid metaplasia. , 1979, Blood.

[13]  G. Pangalis,et al.  Acute (“malignant”) myelosclerosis , 1979, Cancer.

[14]  P. Nowell,et al.  Cytogenetics of acute and chronic myelofibrosis , 1978, Virchows Archiv. B, Cell pathology.

[15]  P. Fialkow,et al.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.

[16]  J. Whang‐Peng,et al.  Cytogenetic studies in patients with myelofibrosis and myeloid metaplasia , 1978 .

[17]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[18]  E. Cronkite,et al.  Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia , 1978, American journal of hematology.

[19]  P. Nowell,et al.  Chromosome studies in “preleukemia”. III. myelofibrosis , 1976, Cancer.

[20]  L. Takácsi-Nagy,et al.  Definition, clinical features and diagnosis of myelobibrosis. , 1975, Clinics in haematology.

[21]  D. Borgaonkar.  Cytogenetic studies in myeloproliferative disorders. , 1972, Cytologia.

[22]  L. Weiss,et al.  Chromosomal evidence for the secondary role of fibroblastic proliferation in acute myelofibrosis. , 1970, Blood.

[23]  S. Lewis,et al.  Malignant Myelosclerosis , 1963, Sangre.

[24]  D.,et al.  Regression Models and Life-Tables , 2022 .